Gleevec Articles
Pfizer's SU11248 trial ends early on success
14 February 2005
Novartis shows off strong R&D pipeline at annual conference
31 January 2005
Prolonged efficacy with 800mg Glivec
13 December 2004
BMS-354825 could be challenge to Gleevec?
13 December 2004
UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care
8 November 2004
Kosan's 17-AAG gets Orphan Drug status for CML from FDA
1 November 2004
Novartis nine-month net income leaps 21%
25 October 2004
Novartis to invest $180M in Singapore drug production plant
23 August 2004
US Rx lottery ahead of Medicare benefit
5 July 2004
Novartis says yes to Aventis merger talks
26 April 2004
Indian drugmakers protest Gleevec EMR
24 November 2003
Novartis' sales on track in third quarter; profits rise 7% as Diovan, Gleevec deliver
27 October 2003
Stock Commentary - Europe
9 June 2003
Promising Gleevec combination results
9 June 2003
Estonia won
28 April 2003
Profits flat at Novartis despite sales growth
21 April 2003
Antigenics starts CML study
14 April 2003
Stock Commentary - Europe
13 January 2003
Update - Novartis' Glivec OKed for first-line CML
6 January 2003
Novartis' Glivec gains FDA OK for first-line treatment
6 January 2003
Glivec's promising in myeloproliferative diseases?
19 August 2002
Glivec offers a bonus to grey-haired patients
12 August 2002
VariaGenics losses increase in 2nd quarter
12 August 2002
South Korean drug pricing challenged
12 August 2002
Novartis sales grow 12% in 2nd qtr
29 July 2002
Novartis' Glivec OKed in UK for GISTs
8 July 2002
Somatropin OK for GH deficiency: UK NICE
3 June 2002
Novartis Glivec works in early-stage CML
27 May 2002
NICE: no guidance yet on Novartis' Glivec
27 May 2002
Novartis researchers honored by AACR
15 April 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Gleevec cleared for GIST in USA
11 February 2002
Gleevec cleared for GIST in USA
11 February 2002
Stock Commentary - Europe.
21 January 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Stock Commentary - Europe
14 January 2002
New trial data support first-line use of Novartis' Glivec in CML
14 January 2002
Novartis' Glivec gains EU approval
9 November 2001
Astrazeneca's Iressa shows promise in non-small cell lung cancer
2 November 2001
Update: Novartis files new indication for Gleevec in USA
24 October 2001
Norvartis submits Gleevec sNDA in USA
19 October 2001
Double-digit turnover growth for Novartis
11 October 2001
Canada approves Novartis' Gleevec
27 September 2001
CPMP backs approval of three new drugs
30 July 2001
Stock Commentary - Europe
28 June 2001
Novartis' Glivec gets Swiss approval
27 June 2001
WSJ questions Gleevec's long-term efficacy in CML
26 June 2001
Stock Commentary - Europe
17 May 2001
Update - Novartis' Gleevec approved in the USA
14 May 2001
Glivec is Gleevec in USA
3 May 2001
Glivec shows promise in stromal tumors
6 April 2001
Novartis seeks US/EU approval for Glivec
1 March 2001
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
